The IP Professional's Playbook: Strategic Naming for an AI-Driven Pharma Market in 2026

Pharmaceutical brand naming has evolved beyond merely finding an available word; it is now a complex, high-stakes strategic challenge.

In 2026, shifting market dynamics, increasing regulatory oversight, and the adoption of AI require pharmaceutical intellectual property (IP) and branding teams to adapt their strategies.

We spoke to Larry Rickles, IP Counsel at Moore & Van Allen and Jukka Immonen, Director of Pharma Propositions at Corsearch, two IP leaders from the pharmaceutical sector who share a clear consensus: your expertise is just as essential as the traditional, linear approach to naming becomes obsolete.

Success now requires an integrated strategy that is powered by technology but driven by your judgment.

Here are several critical and actionable insights to help IP leaders trying to navigate pharma naming landscape:

Navigating Trademark Saturation: Trading Speed for Certainty

The primary operational challenge is the surge in Trademark activity. Class 5 Trademark filings increased from about 15,000 to over 35,000 annually by 2025.

This growth has a direct impact on brand development:

• Fewer viable candidates: The pool of globally clearable names is rapidly shrinking.
  
• Extended clearance cycles: Early-stage uncertainty is high, resulting in longer timelines and greater resource allocation for due diligence.

For teams pressured to accelerate their speed to market, managing saturation is a daily reality that must be strategically addressed from day one.

Regulatory Review: The Unpredictable Final Hurdle

Global health authorities, including the U.S. FDA and the European Medicines Agency (EMA), are employing more sophisticated frameworks to assess the safety of drug names.

The challenge lies not in the rigor of the review but in its persistent unpredictability:

• Late-stage objections: Even after extensive pre-clearance, regulatory objections can emerge late in the approval timeline, forcing costly rebranding.‍

Key takeaway: Trademark clearance and regulatory strategy can no longer be sequential; they must be harmonized into a single process that assesses regulatory viability alongside Trademark risk.

AI as a Force Multiplier, Guided by Expertise

AI changes the speed and scale of analysis in modern IP workflows. AI tools facilitate rapid, data-driven analysis of linguistic similarities, global databases, and regulatory data, significantly shortening early-stage screening.

However, there are two inherent limitations to AI:

• Nuanced judgment: Strategic value, creative dimensions, and complex regulatory sensitivities still require seasoned human evaluation.
  
• The Role of AI: AI identifies risk signals and patterns, but does not replace your final decision-making authority. Your experienced judgment remains crucial for strategic success.

Emerging consensus: The most effective naming strategy combines AI-powered analysis to accelerate screening with expert evaluation reserved for strategic decision-making.

Managing the "Instant Result" Expectation

While AI drastically can reduce the time required for initial database screening, it frequently creates a secondary challenge: translating AI's speed into realistic business expectations, allowing IP teams to prove their value to the business..

Marketing and executive teams may misinterpret the speed of AI as a guarantee of instant Trademark clearance.

To combat this, IP professionals must:

• Educate leadership on the critical difference between automated risk identification and nuanced legal clearance.
  
• Establish realistic launch timelines that buffer rapid AI screening with adequate time for human strategic evaluation.
  
• Create transparent communication frameworks that explain why an AI-vetted name might still require manual review due to complex cultural or regulatory sensitivities.

Global Naming: The Non-Latin Script Imperative

The desire for a single global brand name is often hindered by multilingual complexity. Trademark examination standards and linguistic interpretations differ significantly across jurisdictions, making universal clearance a rare achievement. Understanding these regional nuances is vital for effective, localized naming strategies.

Early integration is vital: Neglecting to assess non-Latin scripts (Cyrillic, Chinese, Japanese, etc.) early in the process is a common cause of delays, leading to costly pivots and rebranding after substantial sunk costs.

Integration Is the New Standard for Success

A major strategic shift is the abandonment of the siloed, sequential naming process.

Traditionally, IP, Regulatory, and Patent teams operated independently. Now, your early and continuous collaboration with these teams is essential for meeting the increasingly compressed timelines of modern drug launches.

Actionable Steps for Cross-Functional Alignment

Recognizing the need for integration is only the first step; executing it requires a fundamental shift in daily operations.

To successfully abandon the siloed, sequential naming process, organizations must implement structured collaboration from the very beginning of the product lifecycle.

• Joint kick-off workshops: Require mandatory alignment sessions between IP, Regulatory, and Patent teams before any brainstorming or screening begins.
  
• Centralized digital workspaces: Utilize shared platforms where linguistic, regulatory, and Trademark feedback can be logged and viewed concurrently by all relevant departments.
  
• Unified milestone reviews: Establish hard checkpoints where naming candidates cannot advance to the next stage without simultaneous sign-off from both regulatory and Trademark leads, preventing costly late-stage surprises.

The Bottom Line for Pharma Industry Professionals

The naming landscape is fundamentally different from what it was even five years ago.

Trademark saturation, global complexity, and regulatory scrutiny are all on the rise. While the potential of AI is significant, it also presents an internal challenge: managing business stakeholders' often unrealistic expectations for automation and speed.

For IP and branding professionals preparing for product launches, the message is clear: success depends not just on finding the right name but on implementing an integrated strategy that aligns Trademark, regulatory, and strategic insights from the outset.

The future of pharmaceutical branding relies on calculated risk and collaborative execution. Know what matters. Act on what counts

Learn more about Corsearch Pharma solutions today.

See how PharmaCheck™ accelerates name qualification

From early-stage screening to post-clearance checks, we help you move faster with confidence - while avoiding missteps new, and help you move forward - faster.

Meet the Speakers